Oncolytics Biotech, Inc. Common Shares (ONCY) Stock Price

ONCYStock

$0.50+12.82%52W

Market Cap$65.31M

P/E—

PEG Ratio—

Div yield—

Beta0.84

ONCY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-7.63%

Price vs S&P 500 (4W)-4.18%

VGM Score63.53

Book Value / Share (Quarterly)$0.04

P/TBV (Annual)7.04x

Cash Flow / Share (Quarterly)$-0.18

Price vs S&P 500 (YTD)-4.44%

EPS (TTM)$-0.26

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-0.26

EPS (Annual)$-0.29

ROI (Annual)-449.98%

Cash / Share (Quarterly)$0.11

ROA (Last FY)-157.08%

EBITD / Share (TTM)$-0.26

ROE (5Y Avg)-177.65%

Cash Flow / Share (Annual)$-0.24

P/B Ratio20.04x

P/B Ratio (Quarterly)15.17x

Net Income / Employee (Annual)$-773,721

Net Interest Coverage (TTM)-1311.50x

ROA (TTM)-144.60%

EPS Incl Extra (Annual)$-0.29

Current Ratio (Annual)2.82x

Quick Ratio (Quarterly)2.40x

3-Month Avg Trading Volume2.04M

52-Week Price Return12.82%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.97

P/S Ratio (Annual)393.63x

Asset Turnover (Annual)0.01x

52-Week High$3.18

EPS Excl Extra (Annual)$-0.29

CapEx CAGR (5Y)88.66%

Tangible BV CAGR (5Y)-14.52%

26-Week Price Return-6.78%

Quick Ratio (Annual)2.54x

13-Week Price Return-31.03%

Total Debt / Equity (Annual)0.18x

Current Ratio (Quarterly)2.88x

Enterprise Value$84.11M

Book Value / Share Growth (5Y)-26.82%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1206.45%

Cash / Share (Annual)$0.15

3-Month Return Std Dev74.15%

Net Income / Employee (TTM)$-742,090

ROE (Last FY)-530.00%

Net Interest Coverage (Annual)-33.16x

EPS Basic Excl Extra (Annual)$-0.29

Total Debt / Equity (Quarterly)0.15x

EPS Incl Extra (TTM)$-0.26

Receivables Turnover (Annual)0.00x

ROI (TTM)-384.49%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.42

Price vs S&P 500 (52W)14.17%

Year-to-Date Return-0.90%

5-Day Price Return6.80%

EPS Normalized (Annual)$-0.29

ROA (5Y Avg)-83.59%

Net Profit Margin (Annual)-1164.52%

Month-to-Date Return-3.51%

Cash Flow / Share (TTM)$-0.35

EBITD / Share (Annual)$-0.32

Operating Margin (Annual)-1206.45%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-160.53%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.26

P/TBV (Quarterly)21.79x

P/B Ratio (Annual)17.13x

Book Value / Share (Annual)$0.05

Price vs S&P 500 (13W)-31.95%

Beta0.84x

Revenue / Share (TTM)$0.00

ROE (TTM)-440.39%

52-Week Low$1.05

mGradeB

vgmGradeB

ONCY Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.05	-$0.08	-47.01%(-$0.03)
Q1 2026	May 14, 2026	-$0.04	-$0.08	-83.12%(-$0.04)
Q3 2025	Nov 12, 2025	-$0.05	-$0.10	-108.18%(-$0.05)
Q2 2025	Aug 8, 2025	-$0.06	-$0.05	+17.33%(+$0.01)

ONCY Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.88

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ONCYOncolytics Biotech, Inc. Common Shares	—	—	B	—	—	—	—	$0.50
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Oncolytics Biotech, Inc. Common Shares

Oncolytics Biotech is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. Its lead candidate, pelareorep, enhances immune response to make tumors more susceptible to existing oncology treatments. The company's pipeline includes programs targeting breast cancer and gastrointestinal cancers across multiple indications.